# Pemvidutide (ALT-801): Altimmune's GLP-1/Glucagon Dual Agonist for MASH and Obesity — Research Profile 2026
Disclaimer: This article is for research and educational purposes only. Pemvidutide (ALT-801) is an investigational compound that has not received FDA approval for any indication. It holds FDA Breakthrough Therapy Designation for MASH. Research into pemvidutide is ongoing in Phase 3 trials. This profile is intended for researchers and scientists studying metabolic disease pharmacotherapy.
---
Overview
Pemvidutide (research name ALT-801) is an investigational peptide developed by Altimmune, Inc. that functions as a balanced dual agonist targeting both the glucagon-like peptide-1 receptor (GLP-1R) and the glucagon receptor (GcgR) in a near 1:1 activity ratio. Unlike the GLP-1/GIP dual agonism of tirzepatide or the GLP-1/GIP/glucagon triple agonism of retatrutide, pemvidutide represents a pure balanced glucagon + GLP-1 approach — designed to exploit glucagon's direct hepatic metabolic effects alongside GLP-1's appetite suppression.
Key distinguishing features of pemvidutide include:
- •Balanced 1:1 GLP-1R/GcgR co-agonism (vs. GLP-1-dominant in survodutide)
- •Pegylation for weekly dosing via Altimmune's proprietary EuPort™ technology
- •FDA Breakthrough Therapy Designation for MASH (metabolic dysfunction-associated steatohepatitis)
- •FDA Fast Track Designation for MASH and alcohol use disorder (AUD)
- •Phase 3 PERFORMA trial initiated August 2026 for MASH
Pemvidutide has also demonstrated efficacy in obesity (MOMENTUM Phase 2) and alcohol use disorder (RECLAIM Phase 2), making it one of the most versatile investigational agents in the GLP-1/glucagon class.
---
The GLP-1/Glucagon Dual Agonism Rationale
Why Add Glucagon Receptor Agonism?
Glucagon is classically understood as insulin's physiological antagonist — the pancreatic hormone that raises blood glucose during fasting. This catabolic hormone role makes glucagon receptor agonism seem counterintuitive as a therapeutic strategy in metabolic disease. However, beyond its glycemic effects, glucagon has profound and beneficial actions on hepatic lipid metabolism and energy expenditure:
Hepatic fat reduction: Glucagon receptor activation directly promotes:
- •Hepatic fatty acid oxidation (β-oxidation)
- •Inhibition of lipogenesis (fat synthesis)
- •Stimulation of lipoprotein export from the liver
- •Reduction in hepatic triglyceride content
These effects make glucagon receptor agonism particularly attractive for MASH — a disease defined by excessive hepatic fat accumulation that can progress to fibrosis, cirrhosis, and hepatocellular carcinoma.
Energy expenditure: Glucagon increases thermogenesis via brown adipose tissue activation and raises basal metabolic rate — a mechanism complementary to GLP-1's appetite suppression. This dual approach (eat less + burn more) theoretically produces weight loss with favorable body composition effects.
The counterweight problem: Pure glucagon receptor agonists cannot be used therapeutically because unmitigated glucagon signaling raises blood glucose. The solution in pemvidutide is to pair GcgR agonism with GLP-1R agonism — which lowers blood glucose by stimulating insulin secretion — effectively counterbalancing glucagon's glycemic liability while retaining its beneficial lipid and energy effects.
Lean mass preservation: A critical theoretical advantage of glucagon co-agonism is that glucagon promotes protein catabolism in fasting states, which can paradoxically support lean mass preservation during caloric restriction by increasing fatty acid utilization. Early MOMENTUM data suggested only 21.9% of weight loss attributable to lean mass — a favorable lean mass preservation ratio compared to some GLP-1 monotherapy data.
---
Molecular Design: EuPort™ Technology
Pemvidutide is a synthetic peptide modified for weekly subcutaneous administration using Altimmune's proprietary EuPort™ domain — a structural element that:
1. Binds serum albumin, extending the drug's circulating half-life to support once-weekly dosing
2. Slows absorption from the subcutaneous injection site, smoothing the plasma concentration curve
3. May improve GI tolerability by reducing peak plasma concentrations relative to compounds without such modifications
The EuPort technology is an important engineering consideration: rapid GI adverse events with GLP-1 class agents often correlate with high peak plasma concentrations. By extending the absorption profile, the EuPort domain may contribute to pemvidutide's observed tolerability in clinical trials.
---
Clinical Evidence
MOMENTUM Phase 2 Trial (Obesity)
Altimmune conducted the MOMENTUM Phase 2 trial of pemvidutide in adults with obesity, presenting 48-week results at the American Diabetes Association (ADA) 84th Scientific Sessions (2024).
Key findings at 48 weeks:
- •Statistically significant weight loss versus placebo across all pemvidutide doses
- •Lean mass preservation: Only 21.9% of total weight loss attributable to lean mass — a notable finding given concerns about muscle loss with GLP-1 therapies
- •Robust reductions in serum triglycerides, LDL cholesterol, and blood pressure — cardiometabolic markers beyond weight loss
- •Reduction in liver fat content (measured by MRI-PDFF), consistent with glucagon receptor's direct hepatic effects
- •Glucose homeostasis maintained: no significant changes in fasting glucose despite glucagon receptor agonism — validating the GLP-1 co-agonism counterbalancing concept
- •No imbalances in cardiac events, arrhythmias, or clinically meaningful heart rate increases (a concern with glucagon agonism given glucagon's positive chronotropic effects)
The MOMENTUM data established pemvidutide's efficacy in obesity and, importantly, demonstrated the hepatic and lipid-lowering effects specific to the glucagon receptor component — supporting progression into MASH trials.
IMPACT Phase 2b Trial (MASH)
The IMPACT Phase 2b trial was a multicenter, randomized, double-blind, placebo-controlled study evaluating pemvidutide in 212 adults with MASH (metabolic dysfunction-associated steatohepatitis). Participants were randomized 1:2:2 to receive weekly subcutaneous pemvidutide 1.2 mg, 1.8 mg, or placebo for 48 weeks.
Primary endpoints (assessed at 24 weeks):
1. MASH resolution without worsening of fibrosis
2. Fibrosis improvement by ≥1 stage without worsening of MASH Activity Score (MAS)
24-Week Results (Primary Endpoints):
- •MASH resolution without worsening fibrosis:
- Pemvidutide 1.2 mg: 59.1% vs placebo 19.1% (statistically significant)
- Pemvidutide 1.8 mg: 52.1% vs placebo 19.1% (statistically significant)
- •Fibrosis improvement without worsening MASH: Pemvidutide did NOT achieve statistical significance on this secondary primary endpoint versus placebo at 24 weeks — the result that sent Altimmune's stock down 59% in premarket trading when announced
48-Week Results (Follow-up):
At 48 weeks, the picture improved substantially:
- •Statistically significant improvements in Enhanced Liver Fibrosis (ELF) score and Liver Stiffness Measurement (LSM) versus placebo — established non-invasive markers of fibrosis and hepatic inflammation
- •Continued reductions from week 24 in antifibrotic markers, suggesting the fibrosis benefit requires extended treatment duration
- •Significant reductions in triglycerides and total cholesterol alongside weight and waist circumference improvement
- •Improvements in multiple cardiometabolic risk factors
Lancet publication: The 24-week IMPACT results were published in The Lancet (PIIS0140-6736(25)02304-9, 2025).
Interpretation: The mixed 24-week results likely reflect the timeline of MASH fibrosis resolution — a pathological process requiring months to years to reverse. The 48-week data showing continued improvement in non-invasive fibrosis markers suggests pemvidutide is producing the right biological signals; the question is whether biopsy-confirmed fibrosis improvement (the FDA-preferred endpoint) will be demonstrable at 48–72 weeks in the Phase 3 PERFORMA trial.
RECLAIM Phase 2 Trial (Alcohol Use Disorder)
Altimmune also announced positive topline results from the RECLAIM Phase 2 trial evaluating pemvidutide in patients with moderate to severe alcohol use disorder. The trial met its primary endpoint with a highly statistically significant reduction in heavy drinking days (HDD) versus placebo, with consistent positive results across secondary endpoints.
This finding extends pemvidutide's potential beyond metabolic disease — GLP-1R and glucagon receptor agonism may modulate reward/addiction pathways in a manner relevant to alcohol use disorder, consistent with emerging evidence that GLP-1R agonists reduce alcohol craving and consumption in preclinical and clinical studies.
---
Regulatory Status and Designations
| Designation | Indication | Status |
|---|---|---|
| Breakthrough Therapy Designation | MASH | Granted (FDA) |
| Fast Track Designation | MASH | Granted (FDA) |
| Fast Track Designation | Alcohol Use Disorder | Granted (FDA) |
| FDA approval | None | Not approved |
Breakthrough Therapy Designation is granted by the FDA to drugs that demonstrate preliminary clinical evidence indicating substantial improvement over available therapies on a clinically significant endpoint. For MASH — where the only FDA-approved treatments as of 2025–2026 include resmetirom (Rezdiffra) and some GLP-1 agents — pemvidutide's designation signals the FDA's recognition that its mechanism (balanced GLP-1/glucagon) offers a potentially differentiated approach.
---
PERFORMA Phase 3 Trial (MASH) — Initiated August 2026
Following the positive 48-week IMPACT data and FDA feedback, Altimmune initiated the PERFORMA Phase 3 trial of pemvidutide for MASH in August 2026.
Trial design:
- •Global, randomized, double-blind, placebo-controlled, parallel-group study
- •Patients: MASH with moderate to advanced fibrosis (F2/F3)
- •Primary endpoints: Fibrosis improvement AND MASH resolution (the two-endpoint approach consistent with FDA guidance)
- •Novel feature: AI-assisted liver biopsy assessment to standardize pathology evaluation across global sites
- •Duration: Expected 48–72 weeks (biopsy-confirmed endpoints require extended follow-up)
The PERFORMA design reflects lessons from the IMPACT trial: the fibrosis endpoint requires sufficient treatment duration and the appropriate patient population (F2/F3 fibrosis) to demonstrate meaningful histological change.
---
Comparison to Other GLP-1/Glucagon Dual Agonists
The GLP-1/glucagon dual agonist class is increasingly competitive. Key comparators to pemvidutide include:
Survodutide (Boehringer Ingelheim)
Survodutide is a glucagon receptor/GLP-1R dual agonist that completed Phase 3 trials (SYNCHRONIZE program) in MASLD/MASH. Key published data (Nature Medicine, 2026):
- •SYNCHRONIZE-MASLD: Liver fat normalization (<5%) in 61% of survodutide patients vs 5.7% placebo at 48 weeks
- •Co-primary endpoints met: ≥30% MRI-PDFF liver fat reduction and body weight reduction
Pemvidutide vs. survodutide: Survodutide has more published Phase 3 data; pemvidutide has a Breakthrough Therapy Designation (suggesting potentially stronger FDA engagement) and a more balanced GcgR:GLP-1R ratio. Survodutide has been characterized as GLP-1-dominant in some analyses. The clinical implications of this ratio difference are under investigation.
Retatrutide (Eli Lilly)
Retatrutide is a triple agonist (GLP-1R + GIPR + GcgR) in Phase 3 trials for obesity. Its glucagon component adds hepatic effects similar to pemvidutide, but its broader receptor coverage produces significantly greater weight loss (~24% at 48 weeks). Pemvidutide's advantage is its specific focus on MASH efficacy and established AUD data.
Mazdutide and Cotadutide
Mazdutide (GLP-1R/GcgR, Innovent Biologics) and cotadutide (GLP-1R/GcgR, AstraZeneca) are dual agonists in various stages, primarily showing MASH and metabolic data in Asian populations.
---
Lean Mass Preservation: A Key Differentiator?
One of the most discussed findings from MOMENTUM was the lean mass preservation data: only 21.9% of weight loss attributable to lean mass with pemvidutide. For comparison:
- •GLP-1 monotherapy (semaglutide, tirzepatide) studies suggest 25–39% of weight loss comes from lean mass
- •Some dual/triple agonists show lean mass sparing comparable to pemvidutide
This finding is mechanistically plausible: glucagon receptor agonism increases hepatic fat oxidation and mobilizes adipose tissue fat, potentially sparing muscle protein. However, body composition results from Phase 2 studies require Phase 3 confirmation with standardized DEXA or MRI measurements across larger, more diverse populations.
---
Research Interest: Why Researchers Study GLP-1/Glucagon Agonists
The GLP-1/glucagon dual agonist approach is particularly attractive for research in:
1. MASH pathophysiology: MASH is driven by hepatic lipid accumulation, insulin resistance, oxidative stress, and inflammatory signaling. Glucagon receptor activation addresses hepatic lipid accumulation through multiple mechanisms (fatty acid oxidation, lipogenesis inhibition) that complement GLP-1's insulin sensitization effects.
2. Cardiometabolic risk beyond glucose: The triglyceride-lowering, HDL-raising, and blood pressure effects of glucagon co-agonism are well-documented in MOMENTUM. Researchers studying the full cardiometabolic risk profile of obesity-related disease are interested in whether these effects translate to cardiovascular outcome benefits (data pending).
3. Alcohol-liver interaction: The RECLAIM data raise mechanistic questions about how GLP-1R and GcgR agonism interact with the brain reward circuits driving alcohol use — with potential implications for the growing recognition that AUD and metabolic liver disease frequently co-occur.
4. Drug design principles: The 1:1 GcgR:GLP-1R ratio of pemvidutide, compared to GLP-1-dominant ratios in other agents, provides a clinical experiment in how ratio-tuning affects efficacy, tolerability, and organ-specific effects. This research will inform next-generation dual and triple agonist design.
---
Summary
Pemvidutide (ALT-801) is Altimmune's once-weekly subcutaneous GLP-1/glucagon balanced dual receptor agonist, with FDA Breakthrough Therapy Designation for MASH and Fast Track Designation for MASH and alcohol use disorder. Key clinical data include: MOMENTUM Phase 2 obesity trial demonstrating weight loss with favorable cardiometabolic and lean mass preservation effects; IMPACT Phase 2b MASH trial showing significant MASH resolution at 24 weeks (59.1% vs 19.1% placebo) and continued antifibrotic improvements at 48 weeks; and RECLAIM Phase 2 demonstrating reduction in heavy drinking days in AUD. The PERFORMA Phase 3 registrational trial for MASH was initiated in August 2026, incorporating AI-assisted liver biopsy assessment. Pemvidutide represents one of the leading investigational agents targeting the hepatic manifestations of metabolic disease through the unique mechanism of balanced glucagon and GLP-1 receptor co-agonism.
---
References
1. IMPACT Phase 2b trial: Safety and efficacy of pemvidutide for MASH. The Lancet 2025;PIIS0140-6736(25)02304-9. [ScienceDirect]
2. ALT-801 in NASH mouse model. PMC9035150. doi: 10.1016/... [PMC]
3. Altimmune press release: MOMENTUM 48-week obesity data at ADA 84th Scientific Sessions (2024)
4. Altimmune press release: IMPACT Phase 2b positive topline 48-week results (2025)
5. Altimmune press release: RECLAIM Phase 2 positive topline results in AUD (2025)
6. Altimmune press release: PERFORMA Phase 3 trial initiation (August 2026)
7. Survodutide SYNCHRONIZE-MASLD Phase 3. Nature Medicine 2026. doi: 10.1038/s41591-026-04479-3
8. HCPLive: "Pemvidutide Shows Continued Antifibrotic Activity for MASH, Progresses to Phase 3 Trial" (2026)
This article is for research and educational purposes only. Pemvidutide is an investigational compound not approved for any indication. Not for human use.
---
Research References
Pemvidutide and GLP-1/glucagon dual agonist research:
- •PMID 41113119: Pemvidutide pharmacology and dual GLP-1/glucagon receptor agonism.
- •PMID 39002641: ALT-801 metabolic effects and therapeutic potential.
- •PMID 42722378: GLP-1/glucagon dual agonist clinical development.